NeuroMab™ Anti-Tau Oligomer BBB Shuttle Antibody(NRZP-1022-ZP3125)

Figure 1 T2286, a novel tau oligomer-specific antibody, detects only tau oligomers, but not monomeric tau or tau fibrils; furthermore, it does not detect oligomers from other proteins.

Figure 2 Tau oligomers in AD patients.

Western blot of PBS soluble fraction from AD & control brain samples (frontal cortex). It is clear that tau oligomers detected by T-2286 are elevated in AD brain (red) compared to control brain (blue), it is clear that T-2286 dosn't recognize monomeric tau.

Figure 3 T2886 detects tau oligomers in PBS sections of AD brains.

T2886 only recognizes higher molecular weight species and not monomer. (B) Tau 5 detects total tau including the monomer. (C) To determine the conformational specificity of T2286, almost no signal was detected after urea treatment.

Figure 4 Biochemical analysis of Tau oligomers. Alkaline phosphatase had limited effect on tau oligomers from AD brain as assessed by T2285 signal compared to using 3 phospho-epitopes. PBS brain homogenate analyzed by WB, (1) untreated, (2) treated with 400 U/ml, (3) with 800 U/ml phosphatase.

Figure 5 Detection of Tau oligomers in Lewy body dementia (LBD) and Alzheimer's disease (AD) samples using the T2286 antibody composition. T2286;

Figure 6 Tau oligomer monoclonal antibody (TOMA) reduces Tau oligomer toxicity.

Tau oligomers are toxic, tested in SY5Y cells. The toxicity can be prevented by TOMA 1-Tau monomer; 2- Tau fibrils; 3- Tau oligomers 4- Tau oligomer+TOMA.

Figure 7 Tau oligomers were detected in the cerebrospinal fluid (CSF) of AD patients.

As shown in Fig.6 using T2286, this figure using TOMA confirms that tau oligomers are elevated in the CSF of AD patients vs. controls, measured by ELISA.